Table 1. Relationship between miR-34a expression level and clinicopathological features of MBC patients.
| Demographic and Histopathologic variables (n) | miR-34a expression levels | P value | |
|---|---|---|---|
| miR-34a+ (≥0.74) | miR-34a− (<0.74) | ||
| Subjects (%) | 17 (35.4) | 31 (64.6) | 0.001 |
| Age (yrs.) | |||
| < mean (27) | 10 (20.8) | 17 (35.4) | 0.517 |
| ≥ mean (21) | 7 (14.6) | 14 (29.2) | |
| Tumor histology | |||
| Ductal (30) | 3 (9.1) | 27 (80.1) | 0.238 |
| Lobular (3) | 1 (3.0) | 2 (6.1) | |
| Tumor Size | |||
| ≤ 3 cm (4) | 2 (6.1) | 2 (6.1) | 0.08 |
| 3-9 cm (24) | 2 (6.1) | 22 (66.6) | |
| ≥ 9 cm (5) | 0 (0) | 5 (15.2) | |
| Diagnosis stage (TNM) | |||
| Stage II (15) | 0 (0) | 15 (45.5) | 0.075 |
| ≥ Stage III (18) | 4 (12.1) | 14 (42.4) | |
| Node status | |||
| Negative (26) | 3 (8.6) | 23 (65.7) | 0.162 |
| Positive (9) | 3 (8.6) | 6 (17.1) | |
| Neoadjuvant therapy (%) | |||
| Yes (12) | 3 (9.4) | 9 (28.1) | 0.399 |
| No (20) | 3 (9.4) | 17 (53.1) | |
| Chemotherapy | |||
| Yes (14) | 3 (9.4) | 11 (34.4) | 0.541 |
| No (18) | 3 (9.4) | 15 (46.9) | |
| PR | |||
| Negative (22) | 6 (12.5) | 16 (33.3) | 0.02 |
| Positive (26) | 11 (22.9) | 15 (31.2) | |
| ER | |||
| Negative (18) | 4 (8.3) | 14 (29.2) | 0.121 |
| Positive (30) | 13 (27.1) | 17 (35.4) | |
| P53 | |||
| Negative (34) | 13 (32.5) | 21 (52.5) | 0.60 |
| Positive (6) | 2 (5.0%) | 4 (10.0) | |
| Ki67 | |||
| ≤ 30 (27) | 14 (29.2) | 13 (27.1) | 0.03 |
| > 30 (21) | 3 (6.2) | 18 (37.5) | |
| Her2/neu | |||
| Low/weak (27) | 10 (20.8) | 17 (35.4) | 0.517 |
| Moderate/strong (21) | 7 (14.6) | 14 (29.2) | |
Abbreviations: miR-34a, MicroRNAs-34a; TNM, TNM classification of malignant tumors; ER, estrogens receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.
Data are presented as a number for all others. %, percent of total samples.